Getting your Trinity Audio player ready...

Investors looking for high-risk, high-reward opportunities often turn to stocks trading under $1. These penny stocks, while volatile, can offer significant upside potential. Here are five (5) stocks currently trading under $1 on major exchanges that analysts believe have substantial growth prospects:

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) A leader in genomic medicine, Sangamo is developing gene therapies and CAR-Treg therapies for serious diseases such as Fabry disease and hemophilia A. The company has several clinical-stage product candidates and strategic partnerships with major pharmaceutical companies like Biogen, Pfizer, and Novartis​

FTC Solar, Inc. (NASDAQ: FTCI) FTC Solar specializes in solar tracker systems and engineering services, offering solutions that improve the efficiency of solar installations. With a diverse customer base and operations in multiple regions, FTC Solar is positioned well for growth in the renewable energy sector​.

Catheter Precision Inc. (NYSE AMERICAN: VTAK) focuses on developing innovative medical devices for cardiac procedures. Its flagship product, VIVO™ (View Into Ventricular Onset), enhances the accuracy of cardiac ablation by mapping ventricular arrhythmias pre-surgery, leading to improved patient outcomes.

Spruce Biosciences, Inc. (NASDAQ: SPRB) This biopharmaceutical company focuses on developing therapies for rare endocrine disorders, such as congenital adrenal hyperplasia and polycystic ovary syndrome. With multiple products in Phase 2 clinical trials and strategic collaborations, Spruce Biosciences has substantial growth potential​.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Significant based on their advancements in synthetic biology. Ginkgo Bioworks is leveraging its platform to create custom organisms for a variety of industries, including pharmaceuticals, agriculture, and industrial biotechnology. The company’s innovative approach and strategic partnerships position it for strong future growth.

These five (5) stocks have been identified based on their innovative products, strong clinical or technological advancements, and significant market potential, making them compelling options for investors looking for high-risk, high-reward opportunities.